Cargando…
Oligometastatic Disease Detection with (68)Ga-PSMA-11 PET/CT in Hormone-Sensitive Prostate Cancer Patients (HSPC) with Biochemical Recurrence after Radical Prostatectomy: Predictive Factors and Clinical Impact
SIMPLE SUMMARY: The early treatment of oligometastatic disease (OMD) is a promising therapeutic option for prostate cancer as it has the potential of delaying androgen-deprivation therapy (ADT) and disease progression. Next-generation imaging targeting the prostate-specific membrane antigen (PSMA-PE...
Autores principales: | Artigas, Carlos, Diamand, Romain, Shagera, Qaid Ahmed, Plouznikoff, Nicolas, Fokoue, Fabrice, Otte, François-Xavier, Gil, Thierry, Peltier, Alexandre, Van Gestel, Dirk, Flamen, Patrick |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508549/ https://www.ncbi.nlm.nih.gov/pubmed/34638466 http://dx.doi.org/10.3390/cancers13194982 |
Ejemplares similares
-
Peering through the PSMA PET Lens: The Role of the European Association of Urology Biochemical Recurrence Risk Groups after Radical Prostatectomy
por: Leplat, Charles, et al.
Publicado: (2023) -
68Ga-PSMA-PET/CT-based radiosurgery and stereotactic body radiotherapy for oligometastatic prostate cancer
por: Kalinauskaite, Goda, et al.
Publicado: (2020) -
The Role of Ga-68 PSMA PET/CT Scan on Differentiating of Oligometastatic and High Risk Prostate Cancer
por: Erdoğan, Mehmet, et al.
Publicado: (2020) -
Predictors of Bone Metastases at (68)Ga-PSMA-11 PET/CT in Hormone-Sensitive Prostate Cancer (HSPC) Patients with Early Biochemical Recurrence or Persistence
por: Rovera, Guido, et al.
Publicado: (2022) -
(68)Ga-PSMA PET/CT for Patients with PSA Relapse after Radical Prostatectomy or External Beam Radiotherapy
por: von Eyben, Finn Edler, et al.
Publicado: (2021)